Terms: = Thyroid cancer AND PDCD1, CD279, PD-1, PD1, SLEB2, hPD-1, hPD-l, hSLE1 AND Prognosis
70 results:
1. Construction and verification of a histone deacetylases-related prognostic signature model for colon cancer.
Hao L; Lu W; Wu J; Chen Y; Xu D; Wang P
Sci Rep; 2024 Apr; 14(1):8983. PubMed ID: 38637684
[TBL] [Abstract] [Full Text] [Related]
2. A distinct tumor microenvironment makes anaplastic thyroid cancer more lethal but immunotherapy sensitive than papillary thyroid cancer.
Han PZ; Ye WD; Yu PC; Tan LC; Shi X; Chen XF; He C; Hu JQ; Wei WJ; Lu ZW; Qu N; Wang Y; Ji QH; Ji DM; Wang YL
JCI Insight; 2024 Mar; 9(8):. PubMed ID: 38478516
[TBL] [Abstract] [Full Text] [Related]
3. Chronic Lymphocytic thyroiditis with Oncocytic Metaplasia Influences PD-L1 Expression in Papillary thyroid Carcinoma.
Santana VB; Krüger VM; Abrahão MCY; Cantú PLM; Brackmann RL; Pandolfi GM; Marisco LS; Remonatto G; Ferreira LA; Graudenz MS
Head Neck Pathol; 2024 Mar; 18(1):14. PubMed ID: 38457034
[TBL] [Abstract] [Full Text] [Related]
4. K48-linked deubiquitination of VGLL4 by USP15 enhances the efficacy of tumor immunotherapy in triple-negative breast cancer.
Wang X; Deng X; Hu J; Zheng W; Ye D; Zhou X; Fang L
Cancer Lett; 2024 Apr; 588():216764. PubMed ID: 38431034
[TBL] [Abstract] [Full Text] [Related]
5. Construction of disulfidptosis-based immune response prediction model with artificial intelligence and validation of the pivotal grouping oncogene c-MET in regulating T cell exhaustion.
Li P; Wang S; Wan H; Huang Y; Yin K; Sun K; Jin H; Wang Z
Front Immunol; 2024; 15():1258475. PubMed ID: 38352883
[TBL] [Abstract] [Full Text] [Related]
6. Predictive biomarkers for immune-related adverse events in cancer patients treated with immune-checkpoint inhibitors.
Wang J; Ma Y; Lin H; Wang J; Cao B
BMC Immunol; 2024 Jan; 25(1):8. PubMed ID: 38267897
[TBL] [Abstract] [Full Text] [Related]
7. Characteristics and immune checkpoint status of radioiodine-refractory recurrent papillary thyroid carcinomas from Ukrainian Chornobyl Tissue Bank donors.
Bogdanova T; Rogounovitch TI; Zurnadzhy L; Mitsutake N; Tronko M; Ito M; Bolgov M; Chernyshov S; Gulevatyi S; Masiuk S; Yamashita S; Saenko VA
Front Endocrinol (Lausanne); 2023; 14():1343848. PubMed ID: 38260161
[TBL] [Abstract] [Full Text] [Related]
8. Immunophenotyping with high-dimensional flow cytometry identifies Treg cell subsets associated with recurrence in papillary thyroid carcinoma.
Li S; Chen Z; Liu M; Li L; Cai W; Lian ZX; Guan H; Xu B
Endocr Relat Cancer; 2024 Mar; 31(3):. PubMed ID: 38214937
[TBL] [Abstract] [Full Text] [Related]
9. Prognostic significance and immunological role of HPRT1 in human cancers.
Lu Y; Chen R; Zhang H; Sun X; Li X; Yang M; Zhang X
Biomol Biomed; 2024 Mar; 24(2):262-291. PubMed ID: 38159260
[TBL] [Abstract] [Full Text] [Related]
10. APOBEC3C is a novel target for the immune treatment of lower-grade gliomas.
Zhao S; Li Y; Xu J; Shen L
Neurol Res; 2024 Mar; 46(3):227-242. PubMed ID: 38007705
[TBL] [Abstract] [Full Text] [Related]
11. Clinical significance and immune landscape of angiogenesis-related genes in bladder cancer.
Liu G; Zhang T; Gui D; Liu Q
Aging (Albany NY); 2023 Nov; 15(22):13118-13133. PubMed ID: 37988196
[TBL] [Abstract] [Full Text] [Related]
12. thyroid dysfunction induced by anti-pd-1 therapy is associated with a better progression-free survival in patients with advanced carcinoma.
Lu Y; Li Q; Xu L; Zheng Y; Wang Y; Liu Y; Zhang R; Liao L; Dong J
J Cancer Res Clin Oncol; 2023 Dec; 149(18):16501-16510. PubMed ID: 37715029
[TBL] [Abstract] [Full Text] [Related]
13. Novel Dual-Mode NIR-II/MRI Nanoprobe Targeting PD-L1 Accurately Evaluates the Efficacy of Immunotherapy for Triple-Negative Breast cancer.
Liu WL; Zhang YQ; Luo XJ; Zhu YY; Song L; Ming ZH; Zhang LX; Li MJ; Lv RC; Zhang GJ; Chen M
Int J Nanomedicine; 2023; 18():5141-5157. PubMed ID: 37705867
[TBL] [Abstract] [Full Text] [Related]
14. Integrative single-cell transcriptome analysis reveals immune suppressive landscape in the anaplastic thyroid cancer.
Feng C; Tao Y; Yu C; Wang L; Liu X; Cao Y
Cancer Gene Ther; 2023 Dec; 30(12):1598-1609. PubMed ID: 37679527
[TBL] [Abstract] [Full Text] [Related]
15. Simultaneous Presentation of Secondary Adrenal Insufficiency and Primary Hypothyroidism due to Pembrolizumab: A Case Report.
Khatri S; Alom M; Kashfi S; Atallah J; Goswami G
J Investig Med High Impact Case Rep; 2023; 11():23247096231194401. PubMed ID: 37642143
[TBL] [Abstract] [Full Text] [Related]
16. STAT3 inhibition enhances gemcitabine sensitivity in pancreatic cancer by suppressing EMT, immune escape and inducing oxidative stress damage.
Guo H; Hu Z; Yang X; Yuan Z; Gao Y; Chen J; Xie L; Chen C; Guo Y; Bai Y
Int Immunopharmacol; 2023 Oct; 123():110709. PubMed ID: 37515849
[TBL] [Abstract] [Full Text] [Related]
17. A novel pyroptosis-related signature predicts prognosis and indicates immunotherapy in oral squamous cell carcinoma.
Gao Y; Zhang X; Li Y; Gao J; Liu S; Cai H; Zhang J
J Cancer Res Clin Oncol; 2023 Oct; 149(13):12057-12070. PubMed ID: 37421458
[TBL] [Abstract] [Full Text] [Related]
18. A meta-analysis of application of pd-1/PD-L1 inhibitor-based immunotherapy in unresectable locally advanced triple-negative breast cancer.
Zhang W; He Y; Tang Y; Dai W; Si Y; Mao F; Xu J; Yu C; Sun X
Immunotherapy; 2023 Sep; 15(13):1073-1088. PubMed ID: 37337734
[TBL] [Abstract] [Full Text] [Related]
19. A novel immune score model predicting the prognosis and immunotherapy response of breast cancer.
Lv W; He X; Wang Y; Zhao C; Dong M; Wu Y; Zhang Q
Sci Rep; 2023 Apr; 13(1):6403. PubMed ID: 37076508
[TBL] [Abstract] [Full Text] [Related]
20. PD-L1 and MCL-1 markers and the relationship with prognostic characteristics of differentiated thyroid carcinoma.
Zantut-Wittmann DE; Barreto IS; Laus AC; Moreno DA; Moma CA; Maia FFR; Assumpção LVMD; Reis RM
Mol Cell Endocrinol; 2023 Jun; 570():111931. PubMed ID: 37072108
[TBL] [Abstract] [Full Text] [Related]
[Next]
